Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)

• Company Description    Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $0.31 Daily Weekly Monthly 20 Day Moving Average: 1,327,498 shares Shares Outstanding: 78.74 (millions) Market Capitalization: $24.05 (millions) Beta: 1.47 52 Week High: $1.75 52 Week Low: $0.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -44.77% -44.68% 12 Week -67.03% -67.56% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET - BOSTON,MA 02135 USA ph: 617-949-2680 fax: - ir@cuebio.com http://www.cuebiopharma.com

• General Corporate Information    Officers Daniel R. Passeri - Chief Executive Officer and Director Kerri-Ann Millar - Chief Financial Officer Peter A. Kiener - Director Frederick Driscoll - Director Pamela Garzone - Director Peer Information Cue Biopharma, Inc. (CORR.) Cue Biopharma, Inc. (RSPI) Cue Biopharma, Inc. (CGXP) Cue Biopharma, Inc. (BGEN) Cue Biopharma, Inc. (GTBP) Cue Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22978P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 78.74 Most Recent Split Date: (:1) Beta: 1.47 Market Capitalization: $24.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.48 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.77 Price/Cash Flow: - Price / Sales: 3.39 EPS Growth vs. Year Ago Period: 58.82% vs. Previous Quarter: 22.22% Sales Growth vs. Year Ago Period: -35.58% vs. Previous Quarter: -27.25% ROE 12/31/25 - - 09/30/25 - -271.67 06/30/25 - -230.13 ROA 12/31/25 - - 09/30/25 - -118.88 06/30/25 - -111.16 Current Ratio 12/31/25 - - 09/30/25 - 1.66 06/30/25 - 1.60 Quick Ratio 12/31/25 - - 09/30/25 - 1.66 06/30/25 - 1.60 Operating Margin 12/31/25 - - 09/30/25 - -530.75 06/30/25 - -469.35 Net Margin 12/31/25 - - 09/30/25 - -530.75 06/30/25 - -469.35 Pre-Tax Margin 12/31/25 - - 09/30/25 - -530.75 06/30/25 - -469.35 Book Value 12/31/25 - - 09/30/25 - 0.17 06/30/25 - 0.24 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.01 Debt-to-Capital 12/31/25 - - 09/30/25 - 1.41 06/30/25 - 1.04

Powered by Zacks Investment Research ©